ALK and lung adenocarcinoma: By focusing on EGFR/ALK wild‐type patients, we aimed to elucidate molecular mechanisms and potential biomarkers related to PD‐L1 expression and the response to immunotherapy within this specific and clinically significant subgroup of lung adenocarcinoma patients.